
Novartis AG: stock overview
Price
$159.13
November 17, 2026Market cap $304B
What Ploutos Investor adds for Novartis
Part of Ploutos Investor, €9.99 a month
- The full history: 10 fiscal years, from 2016
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
In short
Novartis had revenue of $54.5B in the fiscal year to December 31, 2025 and net income of $14.0B, a net margin of 25.6%. Revenue grew by 2.3% a year on average over the last 5 years. At $159.13 the shares trade at a P/E of 21.7, against a median of 16.6 over the last 5 fiscal years. It has net debt of $20.0B. It pays a dividend yielding 2.57%.
From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 17, 2026.
Its SEC filings- Market cap
- $304B
- 1.91B shares
- P/E
- 21.7
- Today21.7Median16.6
- Revenue, fiscal year
- $54.5B
- +2.3% a year over 5 years
- Net margin
- 25.6%
Worth knowing
What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.
3 fiscal years in figures
Each fiscal year's figures as the company filed them, and the share price at its end.
+9.5% a year over 2 years
Fiscal years in figures
NVS's revenue, profit, cash flow and dividend with each year-end price, from 2016 to 2022, 7 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Key figures
The company's current figures in five groups. Each term is explained behind its ⓘ.
Valuation
- Market cap 3-year median: $206B
- $304B
- Enterprise value
- $324B
- P/E 3-year median: 16.6
- 21.7
- EV / EBIT
- 18.3
- EV / Revenue
- 5.9
- P/B 3-year median: 4.4
- 6.5
- FCF yield 3-year median: 6.7%
- 5.8%
- Earnings yield 3-year median: 6.0%
- 4.6%
Profitability
- Gross margin
- 78.8%
- Operating margin
- 32.4%
- Net margin 3-year median: 25.6%
- 25.6%
- ROIC
- 18.4%
- ROIC, 5-year average
- 12.5%
- ROE, fiscal year
- 30.0%
Growth
- Revenue, yearly change
- +8.4%
- EPS, yearly change
- +21.8%
- FCF, yearly change
- +8.3%
- Revenue, average a year
- +2.3%
- EPS, average a year
- +15.2%
The yearly change compares FY2025 with FY2024.
Balance sheet
- Cash
- $11.4B
- Total debt
- $31.4B
- Net debt
- $20.0B
- Net debt / EBITDA
- 1.1x
- Interest cover
- 15.4x
- Current ratio
- –
Balance sheet of December 31, 2025.
Returns to shareholders
- Dividend yield 3-year median: 3.5%
- 2.57%
- Buybacks
- 3.00%
- Total returned
- 5.57%
- Shares, yearly change
- -3.4%
The company at the SEC
How it is registered and when its fiscal year ends.
- Name at the SEC
- NOVARTIS AG
- CIK
- 1114448
- Exchange
- NYSE
- Industry (SIC)
- 2834 · Pharmaceutical Preparations
- Fiscal year ends
- December 31
- Latest annual report
- December 31, 2025
- Reporting currency
- USD
- Shares
- 1.91B
Other companies: Healthcare
The largest companies of the same sector, each with its own page.
- LLYEli Lilly and Company+0,00%Compare with NVS
- JNJJohnson & Johnson+0,00%Compare with NVS
- ABBVAbbVie+0,00%Compare with NVS
- UNHUnitedHealth+0,00%Compare with NVS
- MRKMerck & Company+0,00%Compare with NVS
- AMGNAmgen+0,00%Compare with NVS
- TMOThermo Fisher Scientific+0,00%Compare with NVS
- ABTAbbott Laboratories+0,00%Compare with NVS
The full analysis
What do Novartis's filings show?
These are Novartis's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
What is NVS's market cap?
Novartis AG's market cap is $304B, at a price of $159.13 on November 17, 2026 and 1.91B shares.
What is NVS's P/E?
NVS's P/E is 21.7, on earnings per share of $7.15 in the fiscal year to December 31, 2025. The median over the last 5 fiscal years was 16.6.
How much revenue does NVS have?
Novartis had revenue of $54.5B in the fiscal year to December 31, 2025. Over the last 5 years it changed by +2.3% a year on average.
Does NVS pay a dividend?
Yes. Novartis paid $4.10 per share over the last 12 months, a yield of 2.57% at today's price. All the figures are in the Dividend section.
Where do the figures come from?
From Novartis AG's SEC filings (its annual report on 20-F) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.